The clock for local governments in Michigan to decide on joining a multi-million dollar opioid settlement has been reset, extending the deadline now to November 5. This settlement, a substantial $720 million from eight opioid drug manufacturers, aims to shore up resources for combating the opioid crisis that has ravaged countless communities. According to a press release from the Michigan Attorney General's Office, the extension offers additional time for municipalities to sign on and secure direct payments.
According to the Michigan Attorney General's Office, Attorney General Dana Nessel, who took office in 2019 with a keen eye on the opioid epidemic, has been vigorously pushing for all eligible local governments to get on board. "Opioid settlement dollars have already proven to make a real difference in our fight against the opioid epidemic," Nessel underscored in a statement that came across as one urging municipalities to act before time runs out. The statement emphasized the importance of all eligible communities taking advantage of the funds, with hopes pinned on the extended deadline to foster greater participation.
The roster of pharmaceutical companies coughing up the settlement includes Mylan (now a piece of Viatris), Hikma, Amneal, Apotex, Indivior, Sun, Alvogen, and Zydus. Their collective payout allows participation for 279 Michigan subdivisions, identified on the Department of Attorney General's website as eligible for a cut of the settlement. Struggling to complete their participation forms, these subdivisions can reach out to the Department via email for help before the looming deadline.
Without a shadow of a doubt, the aggressive pursuit by Attorney General Nessel against those deemed responsible for the opioid crisis has reaped benefits for Michigan, securing more than $1.8 billion in settlements. This influx of cash from pharmaceutical giants and retail pharmacies like CVS, Walmart, and Walgreens, as reported by the Michigan Attorney General's Office, is earmarked for tackling opioid use disorder through treatment and recovery programs.
There's a silver lining in the battle against this epidemic as Michigan sees a dip in overdose deaths—a steep 34% drop between 2023 and 2024. This data, brought to light by the Michigan Department of Health and Human Services, is a telling sign of the positive outcomes when strategic investments are channeled into prevention, treatment, and harm-reduction initiatives. The success, cutting down approximately 1,000 deaths, is an outcome that reiterates the effectiveness of concerted efforts funded by these settlements.
